{
  "docId": "019de076-b731-71da-a78f-007719e300bb",
  "docSlug": "1616e8b22ac58e7f024f1153201d610f",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 9,
  "pageCount": 42,
  "prevPage": 8,
  "nextPage": 10,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "The slide uses a structured table to contrast two distinct patient populations (ALK+ vs ROS1+) across three lines of therapy (1L, 2L, 3L+).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/9",
  "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb",
  "deckJsonHref": "/decks/019de076-b731-71da-a78f-007719e300bb.json",
  "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-9",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.05,
        "y": 0.83
      },
      "kind": "source-note",
      "text": "* Repotrectinib was approved November 2023; ** Not FDA approved, but in NCCN guidelines. 1L, 1st line; 2L, 2nd line; 3L, 3rd line; CNS, central nervous system. Sources (ALK): ... Sources (ROS1): ...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81a241c5-66be-43cc-83ac-b4c26bfa5b60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.9,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "table",
      "text": "Table comparing ALK+ and ROS1+ NSCLC treatment landscapes across 1L, 2L, and 3L+ lines of therapy.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "99800fc5-688d-4d82-a629-39c7b1826664",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "title",
      "text": "Emerging resistance mutations, increasing CNS involvement, and treatment-related adverse events limit utility of approved therapies",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f82ed7bf-588a-4e2b-8a11-2a15bf18ae95",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.05,
        "y": 0.11
      },
      "kind": "title",
      "text": "ALK+ and ROS1+ NSCLC Landscape",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "04d19904-219f-4793-bce3-14225d18f328",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Market Segmentation Pyramid",
      "slug": "market-segmentation-pyramid",
      "agent": null,
      "layer": "slide",
      "matchId": "901f416f-e512-48da-a495-f6bac59f0f4e",
      "evidence": "table/data: Table comparing ALK+ and ROS1+ NSCLC treatment landscapes across 1L, 2L, and 3L+ lines of therapy.",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "1ba5d6c2-486d-4ca4-acbd-cdf1af21e226",
      "evidence": "Structured comparison of two clinical landscapes across therapy lines.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 9,
      "from": 9,
      "beatId": "8ce3a4ab-d75c-452e-affd-27d01d209f99",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The deck presents the problem of emerging resistance mutations, increasing CNS involvement, and treatment-related adverse events.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    },
    {
      "to": 10,
      "from": 4,
      "beatId": "1b4ba678-72a5-41ab-80a1-d0e9467146f7",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The deck presents Nuvalent's approach as a potential solution to the problem.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 9,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a5fd2686-9365-4f77-a28b-41b78335203d",
      "evidence": "The deck presents the limitations of current treatment options and the potential benefits of Nuvalent's approach.",
      "position": 0,
      "objective": "Highlight the limitations of current treatment options and the need for new solutions",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}